Quantitative image analysis reveals the benefits of dapagliflozin on glomerulosclerosis, podocyte effacement and kidney fibrosis in the SDT fatty rat model of diabetic nephropathy.

François Briand¹, Estelle Grasset², Masami Shinohara³, Luiz Cordeiro⁴, Virgile Richard⁴, Nicole Endlich⁵, Tim Endlich⁵, Li Chen⁶, Mathieu Petitjean⁶, Thomas de Bel⁷, Thierry Sulpice²

¹Physiogenex, 280 rue de l'Hers, ZAC de la Masquère, Escalquens 31750, France. Electronic address: f.briand@physiogenex.com.

²Physiogenex, 280 rue de l'Hers, ZAC de la Masquère, Escalquens 31750, France.

³CLEA Japan Inc., Tokyo, Japan.

⁴Sciempath Labo, Larçay 37270, France.

⁵NIPOKA GmbH, Walther-Rathenau-Str. 49A, Greifswald 17489, Germany.

⁶PharmaNest, 100 Overlook Center Princeton, NJ 08540, USA.

⁷Aiosyn, Toernooiveld 300 EC, Nijmegen 6525, the Netherlands.

PubMed DOI

Abstract

We aimed to optimize drug efficacy studies in the Spontaneously Diabetic Torii (SDT) fatty rat, a type 2 diabetic model, using kidney histology image analysis with 1) quantitative glomerulosclerosis and tubular impairments (Nephropath AI), 2) Podocyte Exact Morphology Measurement Procedure (PEMP) and 3) quantitative digital pathology of fibrosis (FibroNest platform). To demonstrate the potential o…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.